Skip to main navigation Skip to search Skip to main content

Clinician-led, single-blind, randomised controlled trial evaluating the efficacy of a high-intensity resistance and impact training intervention for improving health-related quality of life in people with multiple sclerosis: protocol for STRONG-MS

  • Lisa Grech (Leading Author)
  • , Belinda Beck
  • , David Scott
  • , Marc Sim
  • , Jakub Mesinovic
  • , Paul Jansons
  • , Fernanda Rodrigues Fonseca
  • , Julie Abimanyi-Ochom
  • , Michelle Allan
  • , Stefan Blum
  • , Ernest Butler
  • , William Carroll
  • , Nigel Caswell
  • , Peter Ebeling
  • , Vanessa Gan
  • , Alan Herschtal
  • , Nevin John
  • , Allan Kermode
  • , Linh Le-Kavanagh
  • , Shalika Bohingamu Mudiyanselage
  • Lynne Elizabeth Ohman, Mia Poposka, Alison Reece, Phoebe Sansom, Charlotte Scroggie, Christopher Todaro, Jennifer Watts, Ayse Zengin (Leading Author)

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Introduction: People with multiple sclerosis (MS) engage in less physical activity and experience higher rates of osteoporosis, falls and fractures than the general population, contributing to reduced health-related quality of life (HRQoL) and increased healthcare costs. High-intensity resistance and impact training (HiRIT) has beneficial effects on bone, muscle and physical function in other populations, but its effectiveness in people with MS is unclear. Methods and analysis: STRONG-MS is a codesigned, clinician-led, single-blind, randomised controlled trial evaluating the effect of a HiRIT programme, ONERO, on HRQoL for people with MS. Secondary aims include assessing changes in bone mineral density, body composition, physical function, fatigue, mood as well as intervention safety, feasibility, acceptability, sustainability and cost-effectiveness. One hundred and eighty participants will be randomised (2:1) to ONERO or usual care for 12 months. The intervention comprises two times weekly, supervised, small-group sessions delivered by accredited allied health professionals. Outcomes will be assessed at 12 and 24 months using intention-to-treat analyses. Sustainability will be evaluated during a second 12-month period, during which participants fund ongoing participation privately or through support schemes. Ethics and dissemination: The study has approval from a Health Human Research Ethics Committee. All participants will provide written informed consent. Findings will be disseminated through peer-reviewed publications, conference presentations and summaries for participants, consumer representatives and community organisations. This study will provide novel evidence on the ability of the ONERO to improve HRQoL and musculoskeletal health in people with MS as well as its feasibility, acceptability and sustainability, to inform poststudy implementation.

Original languageEnglish
Article numbere003181
Number of pages11
Journal BMJ Open Sport and Exercise Medicine
Volume12
Issue number1
DOIs
Publication statusPublished - 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Bone mineral density
  • Exercise
  • Osteoporosis
  • Quality of life

Cite this